miR-378d suppresses malignant phenotype of ESCC cells through AKT signaling
Jie Peng, Susu Shi, Juan Yu, Jianli Liu, Haixiang Wei, Haixia Song, Shaoqiang Wang, Zhejie Li, Shujin He, Lei Li, Hongyan Zhang, Zhizhen Yan, Ran Zhao, Yukun Liu, Yanrong Liu, Junjun Li, Renya Zhang, Wei Wang
Abstract
BACKGROUND: Post-resistance progress in paclitaxel (PTX) treatment remains a major challenge in tumor treatment. A high dose of PTX was used for cell lines to analyze the changes in molecular expression. The miR-378d was sharply reduced in surviving cells, but the role of miR-378d in Esophageal squamous cell carcinoma (ESCC) remained unclear. METHODS: We analyzed the relationship between miR-378d expression and the clinicopathological features of ESCC. We constructed miR-378d silent expression cell lines to study phenotypes and molecular mechanisms. RESULTS: The miR-378d expression was associated with good prognosis in patients with ESCC. miR-378d inhibition promoted chemo-resistance, monoclonal formation, EMT, migration, invasion, stemness, and metastasis of ESCC cells. miR-378d can target downregulated AKT1. CONCLUSIONS: Therefore, miR-378d expression is a good prognostic factor of patients with ESCC and regulates the malignant phenotype of tumor cells through AKT.